Products - Ovarian cancer | Topic | NICE

Showing 1 product

Date | Title

Advice programme: Evidence summariesRemove ‘Advice programme: Evidence summaries’ filter

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)
Product type:
Advice
Programme:
Evidence summary
Published:
22 October 2013